Back to overviewNordberg Medical announces receipt of AMWC 2026 Award for JULÄINE™
JULÄINETM of Sweden, the new and unique PLLA-based injectable receives AMWC 2026 Award for Best Regenerative Aesthetics Solution
:brightness(0))
Swedish biomaterial-based medical device manufacturer Nordberg Medical, proudly announces that it has received the AMWC 2026 Award for Best Regenerative Aesthetics Solution for its new and unique PLLA-based injectable JULÄINE™.
During the 2026 edition of the global Aesthetics Medicine and Anti-Aging World Congress, which took place from March 26 to 28 at the Grimaldi Forum in Monte Carlo, the recently launched PLLA-based injectable JULÄINE™ was recognized as the Best Regenerative Aesthetics Solution worldwide among nine finalists in the award category.
Due to its unique product design, supported by the proprietary LASYNPROTM microsphere technology, our injectable solution JULÄINETM behaves and performs differently to the existing technologies on the market. ’We are very grateful that the quality and the uniqueness of our technology got duly recognized by the AMWC scientific committee and award jury, based on the supporting scientific research and clinical experiences1’, said Jack Yu, CEO of Nordberg Medical.
JULÄINETM stands out due to its unique Poly-L-Lactic Acid-based product design. The formulation consists of very homogeneous spherically shaped microspheres, that have an ultra-smooth surface and are sized within the optimal range of 20–50 microns2. Due to the high molecular weight and high density3, the microspheres maintain their spherical shape for a long time during their slow and controlled degradation4.
The reconstituted JULÄINETM solution contains no foam or debris2 and is easy to inject3, integrates smoothly into the skin4 regenerating natural collagen in a low-inflammatory5 and balanced way, smoothening wrinkles and tightening the skin6, offering cosmetic results that feel authentic and real. ‘Finally, we can now offer our patients a new and unique regenerative medical aesthetics solution that they have been looking for’, says Josine Bolenius, Vice-President of Medical Affairs at Nordberg Medical.
The product has been approved in more than 35 countries worldwide including Europe and APAC and continues to receive additional market access permissions around the globe. ‘We are very much looking forward to be able to offer this Best Regenerative Aesthetics Solution to all injecting health care professionals and patients worldwide’, mentions Jack Yu.
For further information regarding Nordberg Medical and JULÄINETM of Sweden, please visit nordbergmedical.com or julaineofsweden.com or follow us on social media.
About Nordberg Medical
Nordberg Medical, founded in 2017, is an ambitious Swedish biotech company. Internationally present in Europe and APAC, we are rapidly expanding globally as a pioneer in high quality regenerative medical biomaterial science.
Headquartered in Stockholm, with production sites in Uppsala and Malmö, Nordberg Medical leverages a unique Research & Development platform, leading innovative regenerative biomaterial science. Nordberg Medical is partnering with Karolinska Institute of Science in Stockholm, one of the world’s largest leading medical universities, and the national Research Institute of Sweden (RISE).
Excited about new science that matters, we are focused on delivering innovation to the field of bio-regeneration in aesthetics and beyond.
For PR or marketing inquiries:
Kristel Hectors, VP of Marketing & Branding
Swedish biomaterial-based medical device manufacturer Nordberg Medical, proudly announces that it has received the AMWC 2026 Award for Best Regenerative Aesthetics Solution for its new and unique PLLA-based injectable JULÄINE™.
During the 2026 edition of the global Aesthetics Medicine and Anti-Aging World Congress, which took place from March 26 to 28 at the Grimaldi Forum in Monte Carlo, the recently launched PLLA-based injectable JULÄINE™ was recognized as the Best Regenerative Aesthetics Solution worldwide among nine finalists in the award category.
Due to its unique product design, supported by the proprietary LASYNPROTM microsphere technology, our injectable solution JULÄINETM behaves and performs differently to the existing technologies on the market. ’We are very grateful that the quality and the uniqueness of our technology got duly recognized by the AMWC scientific committee and award jury, based on the supporting scientific research and clinical experiences1’, said Jack Yu, CEO of Nordberg Medical.
JULÄINETM stands out due to its unique Poly-L-Lactic Acid-based product design. The formulation consists of very homogeneous spherically shaped microspheres, that have an ultra-smooth surface and are sized within the optimal range of 20–50 microns2. Due to the high molecular weight and high density3, the microspheres maintain their spherical shape for a long time during their slow and controlled degradation4.
The reconstituted JULÄINETM solution contains no foam or debris2 and is easy to inject3, integrates smoothly into the skin4 regenerating natural collagen in a low-inflammatory5 and balanced way, smoothening wrinkles and tightening the skin6, offering cosmetic results that feel authentic and real. ‘Finally, we can now offer our patients a new and unique regenerative medical aesthetics solution that they have been looking for’, says Josine Bolenius, Vice-President of Medical Affairs at Nordberg Medical.
The product has been approved in more than 35 countries worldwide including Europe and APAC and continues to receive additional market access permissions around the globe. ‘We are very much looking forward to be able to offer this Best Regenerative Aesthetics Solution to all injecting health care professionals and patients worldwide’, mentions Jack Yu.
:brightness(undefined))
:brightness(undefined))
For further information regarding Nordberg Medical and JULÄINETM of Sweden, please visit nordbergmedical.com or julaineofsweden.com or follow us on social media.
About Nordberg Medical
Nordberg Medical, founded in 2017, is an ambitious Swedish biotech company. Internationally present in Europe and APAC, we are rapidly expanding globally as a pioneer in high quality regenerative medical biomaterial science.
Headquartered in Stockholm, with production sites in Uppsala and Malmö, Nordberg Medical leverages a unique Research & Development platform, leading innovative regenerative biomaterial science. Nordberg Medical is partnering with Karolinska Institute of Science in Stockholm, one of the world’s largest leading medical universities, and the national Research Institute of Sweden (RISE).
Excited about new science that matters, we are focused on delivering innovation to the field of bio-regeneration in aesthetics and beyond.
For PR or marketing inquiries:
Kristel Hectors, VP of Marketing & Branding
References
2 2025. Kubik P, Gruszczyński W, Filipowska M. Comparative analysis of reconstitution and solubility of two poly-L-lactic acid fillers for medical applications. Polymers; 17(13):1778.
3 2023. The effect of PLLA particles usability, technical and clinical perspectives. Study performed by Research Institute of Sweden AB (RISE). Data on file.
4 2025. PLLA medical device animal implantation study. Data on file
5 2024. Avelar et al. Unveiling the Mechanism: Injectable Poly-L-Lactic Acid’s Evolving Role – Insights From Recent Studies. Journal of Cosmetic Dermatology, 2024; 0:1–4.
6 2025. Urdiales-Gálvez F, Benítez PA, Díaz I. Facial rejuvenation with an innovative poly-l-lactic acid (Juläine) for nasolabial folds: interim data analysis of a prospective, non-randomized, multicenter, open-label Spanish study. J Cosmet Dermatol;24(4):e70137.
Read more related articles
:brightness(0))
:brightness(0))
